

Ellen M Ginzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5892321/publications.pdf>

Version: 2024-02-01

58
papers

6,963
citations

159358

30
h-index

182168

51
g-index

58
all docs

58
docs citations

58
times ranked

4112
citing authors

#	ARTICLE	IF	CITATIONS
1	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42
2	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
3	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
4	Disseminated nocardiosis in an immunosuppressed patient with systemic lupus erythematosus and neuromyelitis optica spectrum disorder. <i>Lupus</i> , 2021, 30, 347-351.	0.8	3
5	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
6	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	2.9	7
7	1124 Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
8	1107 Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
9	801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
10	1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
11	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
12	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
13	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23
14	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
15	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27
16	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.5	40
17	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	1.5	9
18	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	1.5	70
20	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	2.9	25
21	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1125-1134.	2.9	74
22	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	0.9	8
23	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.5	12
24	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	2.9	55
25	Lupus community panel proposals for optimising clinical trials: 2018. Lupus Science and Medicine, 2018, 5, e000258.	1.1	62
26	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	0.9	37
27	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	1.5	55
28	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	1.5	21
29	CS-07â€“...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
30	Dialogue: commentary on â€“Engaging African-ancestry participants in systemic lupus erythematosus clinic trialsâ€“™. Lupus Science and Medicine, 2018, 5, e000306.	1.1	0
31	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis and Rheumatology, 2016, 68, 1932-1944.	2.9	40
32	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	0.9	370
33	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	2.9	98
34	Treatment of systemic lupus erythematosus patients with the BAFF antagonist â€œceptibodyâ€•blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Research and Therapy, 2015, 17, 215.	1.6	48
35	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.5	70
36	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.5	391

#	ARTICLE	IF	CITATIONS
37	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	1.0	149
38	Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xiii-xiv.	0.8	1
39	Management of lupus nephritis—new guidelines revealed. <i>Nature Reviews Rheumatology</i> , 2012, 8, 565-566.	3.5	3
40	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
41	Ataccept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. <i>Arthritis Research and Therapy</i> , 2012, 14, R33.	1.6	245
42	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
43	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 211-221.	6.7	139
44	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, xiii.	0.8	0
45	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
46	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1168-1178.	6.7	515
47	Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2005, 353, 2219-2228.	13.9	991
48	Systemic lupus erythematosus trials: successes and issues. <i>Current Opinion in Rheumatology</i> , 2004, 16, 499-504.	2.0	8
49	Clinical trials in lupus nephritis. <i>Current Rheumatology Reports</i> , 2001, 3, 199-204.	2.1	5
50	Low plasma androgens in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1987, 30, 241-248.	6.7	262
51	A multicenter study of outcome in systemic lupus erythematosus.. <i>Arthritis and Rheumatism</i> , 1982, 25, 601-611.	6.7	320
52	A multicenter study of outcome in systemic lupus erythematosus. ii.. <i>Arthritis and Rheumatism</i> , 1982, 25, 612-617.	6.7	334
53	The clinical significance of raynaud's phenomenon in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1979, 22, 815-819.	6.7	38
54	Effect of Frentizole on Mitogen-Induced Blastogenesis in Human Lymphocytes. <i>Immunopharmacology and Immunotoxicology</i> , 1979, 1, 483-495.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Systemic Lupus Erythematosus in the Older Age Group: Computer Analysis. Journal of the American Geriatrics Society, 1979, 27, 58-61.	1.3	40
56	Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis and Rheumatism, 1978, 21, 37-44.	6.7	264
57	Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis and Rheumatism, 1976, 19, 693-699.	6.7	41
58	Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis and Rheumatism, 1975, 18, 27-34.	6.7	99